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Abstract We have investigated the usefulness of two small
synthetic peptides comprising either a linear or a cyclic
PLAEIDGIEL domain and a DNA-binding moiety of 16 lysine
residues to mediate gene transfer selectively into K9L1-integrin-
displaying cells. Such specific gene delivery could only be
achieved with the peptide containing the cyclic PLAEIDGIEL
domain. However, inclusion of the cationic liposome Lipofect-
AMINE into the peptide/DNA complexes resulted for both
peptides in efficient gene transfer with significant targeting
specificity. Naturally, the integrin K9L1 is present only in a few
highly specialised tissues and abundant throughout the human
airway epithelia in vivo. Targeting gene vectors to this integrin
therefore appears a useful approach to gene therapy of lung
diseases such as cystic fibrosis. As the integrin K9L1 is associated
with tissue differentiation during foetal development and may
cause resurgence of the foetal phenotype in colon cancers, such
vectors may also be applicable for prenatal and cancer gene
therapy.
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1. Introduction
Integrin K9L1, the cell surface receptor for the extracellular
matrix proteins tenascin C [1] and osteopontin [2] and the
vascular cell adhesion molecule-1 [3], is found in highly spe-
cialised tissues, such as squamous epithelia, smooth and skel-
etal muscles and hepatocytes [4]. It has also been reported to
be abundant throughout the human airway epithelia in vivo,
irrespective of any particular clinical status [5], which makes it
interesting for targeted drug or gene delivery to treat lung
diseases such as cystic ¢brosis. During foetal development
K9L1-integrin is associated with the onset of tissue di¡erentia-
tion suggesting a role in the maturation and/or maintenance
of these tissues [6]. Its presence in certain carcinoma cell lines
has been interpreted as a resurgence of the foetal phenotype in
a subset of colon cancers [7]. Hence, K9L1-integrin-targeting
gene therapy vectors may also be applicable for prenatal [8]
and cancer gene therapy.
Recently we localised the K9L1-integrin-binding site of
tenascin C to the B-C loop of its third ¢bronectin type III
repeat (TNfn3) and showed that a synthetic Pro-Leu-Ala-Glu-
Ile-Asp-Gly-Ile-Glu-Leu-Thr-Tyr peptide (PLAEIDGIELTY)
displaced K9L1-integrin-displaying cells completely from bind-
ing to recombinant TNfn3 [9,10]. This peptide, therefore, ap-
peared a promising candidate domain for the development of
gene therapy vectors targeting the integrin K9L1. Here we
show that targeted gene delivery into K9L1-integrin-displaying
cells can be achieved with a synthetic peptide comprising a
cyclic CPLAEIDGIELC domain and a DNA-binding moiety
of 16 lysine residues.
2. Materials and methods
2.1. Cell lines, plasmids and synthetic peptides
The human colon carcinoma cell line SW480 either displaying K9L1-
integrin after being stably transformed with pcDNAIneoK9 or lacking
this integrin (mock-transfectants) [1] was grown in Dulbecco’s modi-
¢ed Eagle’s medium (DMEM) containing 10% foetal calf serum
(FCS), penicillin (100 U/ml), streptomycin (100 U/ml) and G418 (1
mg/ml). All tissue culture reagents were purchased from Life Tech-
nologies, Paisley, UK.
The pGEX expression plasmid encoding a TNfn3/glutathione
S-transferase fusion protein [11] was obtained from Dr. Kathryn L.
Crossin (Scripps Research Institute, La Jolla, CA, USA). Recombi-
nant TNfn3 was produced in Escherichia coli and puri¢ed as described
previously [9].
The peptide PLAEIDGIELTY was purchased from Genosys
Biotechnologies Inc., Cambridge, UK. The peptides K[16]-
GGPLAEIDGIELGA, K[16]-GCPLAEIDGIELCA (disulphide-cy-
clised) and K[16] were synthesised by A⁄niti Research Products, Ex-
eter, UK. Their ability to bind DNA was shown by adding increasing
amounts of peptide to a constant amount of plasmid DNA followed
by analysis on a 1% agarose gel indicating the amount of peptide
required for the complete retardation of the electrophoretic mobility
of 1 Wg plasmid DNA ( = 1 retardation unit).
2.2. Competitive cell binding inhibition assays
Individual wells of non-tissue culture-treated polystyrene 96-well
microtitre plates were coated by incubation with recombinant
TNfn3 for 1 h at 37‡C, washed three times with phosphate-bu¡ered
saline (PBS) and then blocked with 1% bovine serum albumin (BSA)
in PBS for 1 h at 37‡C. K9L1-Integrin-displaying SW480 cells, har-
vested when sub-con£uent, were washed with DMEM and re-sus-
pended in DMEM containing 0.5% BSA. Aliquots of the cell suspen-
sion were pre-treated by mixing with the indicated peptides for 15 min
at 4‡C. Following addition of 5U104 cells to each well, the plates were
spun in a centrifuge at 10Ug for 5 min and incubated for 1 h at 37‡C,
5% CO2. Non-adherent cells were removed by centrifugation of the
plate top-side down at 48Ug for 5 min. The attached cells were ¢xed
with 1% formaldehyde and stained with 0.5% (w/v) crystal violet [12].
Excess stain in the wells was thoroughly washed away with PBS. After
air-drying the cells were solubilised in 2% Triton X-100 and quanti¢ed
by measuring the absorbance at 595 nm.
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 1 8 1 - 3
*Corresponding author. Fax: (44) (171) 5943015.
E-mail: h.schneider@ic.ac.uk
Abbreviations: TNfn3, third ¢bronectin type III repeat of tenascin C;
DMEM, Dulbecco’s modi¢ed Eagle’s medium; PBS, phosphate-bu¡-
ered saline; BSA, bovine serum albumin; FCS, foetal calf serum
FEBS 22623 16-9-99
FEBS 22623 FEBS Letters 458 (1999) 329^332
2.3. Gene transfer experiments
The American ¢re£y luciferase gene under the control of a simian
virus 40 promoter and enhancer in the plasmid vector pGL3 (Prom-
ega, Madison, WI, USA) was used as reporter gene. Plasmid DNA
was puri¢ed from overnight cultures of transformed E. coli DH5K
using an endotoxin extraction kit (Qiagen, Hilden, Germany). Cells
were seeded in tissue culture-treated 24-well plates at a density of
5U104/well and incubated for approximately 12 h until 50% con£u-
ent. Peptide-DNA and peptide-DNA-LipofectAMINE complexes
were prepared in 50 Wl of serum-free OptiMem medium (Life Tech-
nologies, Paisley, UK). The cells were washed and incubated in Opti-
Mem for 30 min at 37‡C before addition of the complexes and further
incubation for 4 h. The medium was then replaced by DMEM con-
taining 10% FCS supplemented with penicillin (100 U/ml), streptomy-
cin (100 U/ml) and G418 (1 mg/ml) and the incubation was continued
for an additional 44 h. Luciferase activity was determined after har-
vesting the cells in 200 Wl of reporter lysis bu¡er (Promega, Madison,
WI, USA) using the luciferase assay kit from Promega and a Berthold
luminometer.
2.4. Statistical analysis
Each result of gene transfer experiments represents the mean
( þ S.E.M.) of at least four independent assays each performed in
sextuplicate. Statistical analysis was done using the non-parametric
rank test of Wilcoxon. Probability values 6 0.05 were considered to
be statistically signi¢cant.
3. Results and discussion
Aiming to improve the targeting of our established non-
viral integrin-mediated gene transfer systems [13,14] to air-
way epithelia, we synthesised two peptides each comprising
a receptor-targeting domain (either disulphide-cyclised
CPLAEIDGIELC or linear GPLAEIDGIELG) and a
DNA-binding moiety consisting of 16 lysine residues.
Previous binding competition studies had revealed that a
linear version of the PLAEIDGIEL domain on its own
blocked the adhesion of K9L1-integrin-displaying cells to re-
combinant TNfn3 better than a cyclic one. This indicated that
the linear structure was advantageous due to its ability to
adapt to conformational requirements for that binding (data
not shown). Surprisingly, in ¢rst gene transfer assays speci¢c
gene delivery into K9L1-integrin-displaying SW480 cells could
only be achieved with the cyclic CPLAEIDGIELC-K[16] pep-
tide and the transfection e⁄ciency was relatively low when
compared with other systems for receptor-mediated gene
transfer developed in our lab [14,15]. Therefore we investi-
gated whether the positively charged polylysine tail in£uences
the binding of the PLAEIDGIEL domain to K9L1-integrin.
These experiments showed that the coupling of K[16] to the
linear GPLAEIDGIELG domain leads to a drastic weakening
of its binding to K9L1-integrin. While the linear peptide with-
out K[16] tail displaced K9L1-integrin-displaying SW480 cells
completely from their binding to recombinant TNfn3, its
equivalent with K[16] tail at a concentration of 1 mM reduced
that binding only by 33%. In contrast, the peptide with the
cyclic head group and K[16]tail at the same concentration
diminished the adhesion of K9L1-integrin-displaying SW480
cells by 57% (Fig. 1).
The di¡erence between the linear and the cyclic peptide may
be due to a conformation change of the negatively charged
linear head group after coupling with the positively charged
K[16] tail, e.g. the shape and function of the head group may
be neutralised like a closed pocket knife, which appears to
occur to a lesser extent with the disulphide-constrained cyclic
head group.
Repeated gene transfer assays con¢rmed that the peptide
with the cyclic CPLAEIDGIELC domain mediates speci¢c
gene delivery into K9L1-integrin-displaying SW480 cells (Fig.
2), whereas there was no consistently signi¢cant di¡erence
between cells displaying K9L1 and cells lacking this integrin
when the linear peptide was used (data not shown). Com-
plexes formed with two retardation units of the cyclic peptide
Fig. 1. E¡ects of di¡erent peptides containing a PLAEIDGIEL do-
main on the attachment of K9L1-integrin-displaying SW480 cells to
TNfn3. Individual wells of 96-well plates were coated with recombi-
nant TNfn3 and blocked with BSA. 5U104 K9L1-integrin-displaying
SW480 cells pre-treated with the indicated peptides were added to
each well (triplicate wells for each peptide) and the plates were incu-
bated for 1 h at 37‡C, 5% CO2. Non-adherent cells were removed
by centrifugation of the plate top-side down. The attached cells
were ¢xed with 1% formaldehyde, stained with crystal violet, solubi-
lised in 2% Triton X-100 and quanti¢ed by measuring the absorb-
ance at 595 nm. Error bars indicate the standard deviation.
Fig. 2. K9L1-Integrin-mediated delivery of a luciferase reporter gene
plasmid using a cyclic K[16]-GCPLAEIDGIELCA peptide. Peptide-
pGL3 complexes containing one, two or four retardation units of
the peptide (retardation unit = the amount of peptide required for
complete retardation of the electrophoretic mobility of 1 Wg of plas-
mid DNA) formed in HEPES-bu¡ered saline were incubated with
semi-con£uent cells on 24-well dishes for 4 h at 37‡C. Following
further incubation for an additional 44 h, luciferase activity in the
cell lysates was determined. Each column represents the average re-
sult of four experiments each performed in sextuplicate (black col-
umns: SW480 cells displaying K9L1-integrin; white columns: SW480
cells lacking this integrin). Error bars indicate the S.E.M.
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were found to deliver a luciferase reporter gene one order of
magnitude more e⁄ciently into K9L1-integrin-displaying cells
than complexes formed with two retardation units of K[16]
(Fig. 2). However, the cationic liposome LipofectAMINE that
served as assay standard gave on average 200-fold higher
reporter gene expression values than the optimal amount of
the cyclic peptide on K9L1-integrin-displaying cells.
As time course studies revealed highly K9L1-integrin-speci¢c
transfection after vector-cell contact for 120^240 min, but in-
creasing unspeci¢c transfection with longer contact times
(data not shown), we standardised our gene transfer assays
at cell contact times of 2^4 h. We tried to improve the e⁄-
ciency of the gene transfer by including the cationic lipid
LipofectAMINE into the peptide/DNA complexes, which
has been demonstrated to enhance the transfection mediated
by our RGD-prototype system for integrin-mediated gene
transfer [16]. Optimisation experiments showed that the gene
transfer e⁄ciency achieved with LipofectAMINE can be in-
creased more than one order of magnitude by complexing the
cyclic peptide with LipofectAMINE and DNA using lipid/
DNA ratios between 12:1 and 24:1 (w/w). However, as with
our model system [16] this increase in e⁄ciency was associated
with reduced, but still signi¢cant (P6 0.05) cell speci¢city
(Fig. 3). Thus, in the presence of LipofectAMINE internal-
isation of the complex occurs to a large extent by an integrin-
independent mechanism. Nevertheless, with respect to in vivo
application of K9L1-integrin-targeting peptides such combina-
tion appears to be a promising approach.
Interestingly, the lipid enhancement also allowed targeting
speci¢city to be achieved with the linear peptide. Pooled data
from four experiments each performed in sextuplicate showed
2.1-fold better transfection with K[16]-GGPLAEIDGIELGA/
LipofectAMINE than with K[16]/LipofectAMINE on K9L1-
integrin-displaying cells (P6 0.05) and 1.9-fold higher e⁄-
ciency of K[16]-GGPLAEIDGIELGA/LipofectAMINE on
K9L1-integrin-displaying cells than on control cells lacking
this integrin (P6 0.05).
In contrast to previously developed peptides for integrin-
mediated gene transfer [13,14,17,18] which display the argi-
nine-glycine-aspartic acid (RGD) motif recognised by a broad
variety of receptors, PLAEIDGIEL-containing vectors target
only one receptor, the integrin K9L1. Thus, the results of this
study prove the possibility of generating vectors for the tar-
geting of individual integrins.
The peptide vectors developed so far represent the ¢rst
generation of synthetic virus-like particles: they mimic viruses
by using integrins to enter cells and also by literally ‘pack-
aging’ DNA within a complex of a size equivalent to a virus,
and thus protecting the DNA from degradation by nucleases
[14]. Our peptides, however, avoid some crucial problems in-
herent in viral gene therapy vectors, such as limited capacity
for foreign DNA, contamination of virus preparations with
wild type/helper virus, and induction of immune responses
(Harbottle et al., unpublished data). They can be considered
to be modular multifunctional systems with greater £exibility
because they allow the combination of any given plasmid
DNA with several peptides harbouring di¡erent functions,
which can be adapted to a particular gene transfer request,
in a given disease [19]. As internalisation into cells may occur
by a phagocytosis-like ‘zippering-up’ mechanism without spe-
ci¢c limitation to the size of the particle [14], systems for
integrin-mediated gene transfer appear to be suitable for e⁄-
cient introduction of mammalian arti¢cial chromosomes into
cells.
The development of targeted non-viral vectors is one of the
main current strategies in gene therapy research. Although
systems for receptor-mediated gene transfer have not yet
reached the gene transfer e⁄ciency of the best viral vectors,
combination with liposomes may facilitate approaching it.
The possibility to synthesise and modify well-de¢ned gene
therapy vectors may therefore be a major advantage of our
synthetic peptides and the data reported here stand as proof
of principle for that.
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